Melanoma News and Research

Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.

Antigenics to withdraw its MAA for Oncophage following CHMP’s negative opinion

20. November 2009 09:28

Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer). [More]

9de2aaf9-d1dc-42a8-8d75-d56e72072c7e|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Biotechnology, Cancer, Cell, Chemotherapy, Glioma, Kidney Cancer, Lymphoma, Melanoma, Oncology, Renal Cell Carcinoma, Vaccine

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

20. November 2009 09:02

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion. [More]

4860eda6-fe31-4d8b-a8a6-7cc875daf80d|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abraxane, Apoptosis, Bone, Cancer, Cell, Chemotherapy, Dacarbazine, DNA, Docetaxel, Evolution, Melanoma, Neutropenia, Oncology, Paclitaxel, Skin Cancer, Temozolomide

Low-level laser therapy increases tumour growth in skin cancer

19. November 2009 22:48

High irradiances of low-level laser therapy (LLLT) should not be used over melanomas. Researchers writing in the open access journal BMC Cancer studied the pain relieving, anti-inflammatory 'cold laser', finding that it caused increased tumour growth in a mouse model of skin cancer. [More]

15dff983-6b6b-427e-b866-d007423410b1|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Anti-Inflammatory, Cancer, Cell, Melanoma, Skin Cancer, Sports Medicine

Recent progress of Delcath Systems in drug delivery platform reported

19. November 2009 07:16

Delcath Systems, Inc., a medical technology company developing the Delcath Percutaneous Hepatic Perfusion (PHP(TM)) System, a minimally invasive drug delivery platform for the regional treatment of cancer metastatic to the liver, today reported on the Company's recent progress. [More]

6259d6a1-b252-41d1-8837-1e07be29b55f|0|.0

Posted in: Device / Technology News

Tags: Adenocarcinomas, Cancer, Colorectal Cancer, Drug Delivery, Liver Cancer, Melanoma, Ocular Melanoma

New biomarkers can predict patients' response to certain drugs

19. November 2009 04:02

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects. [More]

50ccea28-a9bb-4b4c-9116-c045d0269177|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Biomarker, Breast Cancer, Cancer, Cell, Cell Proliferation, Cervical Cancer, Colon Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Oncogene, Ovarian Cancer, Radiotherapy, Renal Cell Carcinoma, Small Cell Lung Cancer, Sorafenib, Tamoxifen, VEGF

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

18. November 2009 09:08

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass. [More]

36558819-deb9-4922-bb20-43e281a8e1fc|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Apoptosis, Cancer, Cell, Chemotherapy, Copper, Hematology, Melanoma, Oxidative Stress, Paclitaxel, Stress

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

18. November 2009 08:40

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models. [More]

7105e9d6-13ab-4fd4-afa9-3e55eccba03a|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Acute Lymphoblastic Leukemia, Apoptosis, Breast Cancer, Cancer, Cell, Chronic Myeloid Leukemia, Colon Cancer, Erlotinib, Gleevec, Hospital, Leukemia, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Myeloid Leukemia, Non-Small Cell Lung Cancer, Oncology, Paclitaxel, Pancreatic Cancer, Prostate Cancer, Small Cell Lung Cancer, Sunitinib, Tarceva, Xenograft

Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

17. November 2009 09:28

Oncolytics Biotech Inc. today announced updated results from a Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers in a poster presentation at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts. [More]

24658c38-d083-44f6-ac3c-f6f6bf6962fd|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Biotechnology, Cancer, Carboplatin, Cell, Chemotherapy, Head and Neck Cancer, Melanoma, Paclitaxel, Squamous Cell Carcinoma

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

17. November 2009 08:04

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany. [More]

1e4e8117-84c9-490f-b3e0-d09c1aace944|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Apoptosis, Atopic Dermatitis, Breast Cancer, Cancer, Cell, Dermatitis, Dermatology, Evolution, Liver Cancer, Melanoma, Metastasis, Oncology, Psoriasis, Skin Cancer

First-quarter fiscal 2010 results announced by IsoRay

16. November 2009 08:58

IsoRay Inc. a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the first quarter of fiscal year 2010, ended September 30, 2009. [More]

b7927b7c-2f23-4dde-82e0-1bb6e57d2cc2|0|.0

Posted in: Business / Finance

Tags: Brachytherapy, Burn, Cancer, Implants, Melanoma, Ocular Melanoma, Oncology, Prostate Cancer

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

16. November 2009 07:49

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities. [More]

b689ae43-2e93-4d5d-89bc-90080a00d0c2|0|.0

Posted in: Business / Finance

Tags: Bladder Cancer, Bone, Cancer, DNA, Docetaxel, Melanoma, Oncology, Osteoporosis, Paclitaxel, Prostate Cancer

Genta announces Phase 3 trial results of Genasense

16. November 2009 07:44

Genta Incorporated today announced preliminary results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine (DTIC) administered with or without Genasense® in patients who have not previously received chemotherapy. [More]

139530a1-5ecb-415e-bc8d-59cf172aeaba|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Biomarker, Bone, Cancer, Chemotherapy, Dacarbazine, DNA, Docetaxel, Melanoma, Neutropenia, Paclitaxel, Thrombocytopenia

CMS approves FDG PET for initial staging of cervical cancer

13. November 2009 01:45

SNM applauds the Centers for Medicare & Medicaid Services- (CMS) decision to expand coverage of FDG PET for the initial staging of cervical cancer without previously imposed restrictions. [More]

8822643a-39fb-4204-ba01-dbbe3ea4b770|0|.0

Posted in: Device / Technology News | Medical Condition News | Healthcare News

Tags: Cancer, Cell, Cervical Cancer, Lymphoma, Medicaid, Medicare, Melanoma, Nuclear Medicine, Oncology, Radiology

Research and Markets' Competitive Intelligence Report on TGF-R agonists and antagonists

11. November 2009 07:53

Research and Markets has announced the addition of the "Competitor Analysis: TGF-R Agonists and Antagonists" report to their offering. [More]

437e0ee1-fcaa-41c1-89f9-02468daf731b|0|.0

Posted in: Medical Science News | Pharmaceutical News

Tags: Antisense, Cancer, Cytokines, Fibrosis, Melanoma, Osteoarthritis, Pancreatic Cancer, Scleroderma, Vaccine, Wound Healing

Report on the emerging market for cancer vaccines

11. November 2009 03:36

This brand new report published in October 2004 provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets. [More]

77d45471-4c05-42e8-b9c7-cc39b3f1f644|0|.0

Posted in: Pharmaceutical News

Tags: Breast Cancer, Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Vaccine

<< Previous posts

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Melanoma News and Research

Antigenics to withdraw its MAA for Oncophage following CHMP’s negative opinion

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Low-level laser therapy increases tumour growth in skin cancer

Recent progress of Delcath Systems in drug delivery platform reported

New biomarkers can predict patients' response to certain drugs

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

First-quarter fiscal 2010 results announced by IsoRay

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta announces Phase 3 trial results of Genasense

CMS approves FDG PET for initial staging of cervical cancer

Research and Markets' Competitive Intelligence Report on TGF-R agonists and antagonists

Report on the emerging market for cancer vaccines

Recent Articles

Free!

Recent Comments

Twitter

Information

Melanoma News and Research

Medical News Cloud

Recent Articles